Scarica l'app Stockscreener
96.07
0.92%
-0.89
Dopo l'orario di chiusura:
96.49
0.42
+0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup - ChartMill
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Incyte Corp stock: What investors should know about its biotech potential now - AD HOC NEWS
Incyte to Report First Quarter 2026 Financial Results - BioSpace
L2 Asset Management, LLC's Incyte Corp(INCY) Holding History - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Corporation (INCY) stock price, news, quote and history - Yahoo Finance UK
Incyte to Report First Quarter Financial Results - ChartMill
Barclays Maintains Overweight on Incyte Corporation (INCY) March 24, 2026 - Meyka
Incyte Corp. stock rises Wednesday, still underperforms market - MarketWatch
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Drug Shows Reduced COPD-like HS Flares in Phase III Data - MyChesCo
Hidradenitis Suppurativa Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte Corp, CSL - Barchart.com
Incyte Names Cagnoni President, Announces Leadership Changes - MyChesCo
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte Corp. (INCY) reports Q4 2025 revenue growth of 28% to $1.51B driven by Jakafi and Opzelura sales - MSN
Allspring Global Investments Holdings LLC Buys 112,736 Shares of Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology CollaborationHas The Bull Case Changed? - Yahoo Finance
Toth Financial Advisory Corp Acquires Shares of 12,280 Incyte Corporation $INCY - MarketBeat
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp - Barchart.com
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key - openPR.com
Incyte reports strong 54-week data from late-stage skin disorder study - MSN
Adagene reveals Incyte deal, data update and public offering - The Pharma Letter
Incyte Corp (INCY) board rep logs 421-share RSU fee grant - Stock Titan
Incyte (INCY) director Edmund Harrigan takes 269-share grant in fees - Stock Titan
Incyte (INCY) director takes 265-share board fee in stock - Stock Titan
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Yahoo Finance
Citizens reiterates Incyte stock rating on pipeline progress By Investing.com - Investing.com South Africa
Citizens reiterates Incyte stock rating on pipeline progress - Investing.com
J. Safra Sarasin Holding AG Decreases Stake in Incyte Corporation $INCY - MarketBeat
Barclays Maintains Overweight on Incyte (INCY) Mar 2026 - Meyka
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - MSN
Incyte Corporation (INCY) Announces Board Member Resignation - GuruFocus
Incyte board member Susanne Schaffert to step down in April By Investing.com - Investing.com India
Incyte board member Susanne Schaffert to step down in April - Investing.com
Incyte's Susanne Schaffert to Resign from Board Effective April 15, 2026 - TradingView — Track All Markets
Incyte (INCY) Board member Susanne Schaffert to step down April 15, 2026 - Stock Titan
INCY: HC Wainwright & Co. Reiterates 'Buy' Rating and $135 Price Target | INCY Stock News - GuruFocus
Incyte Shares Positive 54-Week Results From Advanced Skin Condition Trial - Bitget
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study - Yahoo Finance
William Blair reiterates Market Perform on Incyte stock after HS data - Investing.com Canada
MoonLake and Incyte progress HS prospects at AAD - The Pharma Letter
Stifel reiterates Incyte stock rating on hidradenitis drug data By Investing.com - Investing.com India
Stifel reiterates Incyte stock rating on hidradenitis drug data - Investing.com
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack - Yahoo Finance
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting - BioSpace
0.95%
3.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):